Founded in 1947, Charles River Laboratories International, Inc. (CRL) is a pharmaceutical research services company that now commands a market cap of nearly $16.5 billion. Its portfolio covers laboratory testing, drug discovery, preclinical development, safety assessment, research models, cell therapy development, and manufacturing, giving the company a broad presence across the drug development process.
The Wilmington, Massachusetts-based Charles River is scheduled to report its Q3 FY2026 results on Wednesday, Nov. 4, before the market opens. Analysts are looking for diluted EPS of $2.98, compared with $2.43 in the year-ago quarter. Expectations are buoyed by the company’s recent consistency, with earnings beating analyst estimates in each of the past four quarters.